Project Grant K22HL171175
Award Date 5/1/26
Completion Date 3/31/29
Dollars Obligated $249K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Lexington, KY 40506, USA
Similar Awards
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The University of Kentucky Research Foundation a $538,808 Project Grant (CFDA 93.837: Cardiovascular Diseases Research) beginning September 15, 2025, with completion targeted for June 30, 2030. The research project, "Targeting NINJ1-Mediated Plasma Membrane Rupture to Prevent Thrombosis," will investigate the role of plasma membrane rupture (PMR) in pyroptotic macrophages and its contribution to...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of California, Los Angeles a $2.18 million Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) beginning August 1, 2025, with a completion date of April 30, 2032. This research initiative focuses on elucidating the regulation of intravascular triglyceride hydrolysis and addressing persistent gaps in triglyceride metabolism that contribute to coronary heart disease...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Kentucky Research Foundation a $231,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) effective August 1, 2025, through July 31, 2027. The research will quantify cardiovascular disease (CVD) risk associated with smoking cessation and changes in smoking patterns among a diverse cohort of U.S. adults. The primary deliverables include analyses of repeated...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $713,382 Project Grant to the University of Pennsylvania (primary institution) for research on triglyceride-rich lipoproteins (TRL) and their role in abdominal aortic aneurysm (AAA) growth and progression. Under the Cardiovascular Diseases Research program (CFDA 93.837), this four-year project (August 1, 2025 – July 31, 2029) will deliver scientific research outputs designed to establish...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Louisiana State University Health Sciences Center-Shreveport a Project Grant of $659,441 under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct basic science research investigating nutrient sensing mechanisms in macrophage-mediated clearance of apoptotic cells. The research, which commenced August 15, 2025, and extends through May 31, 2029, seeks to elucidate the molecular pathways...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded New York University's Long Island School of Medicine a Project Grant totaling $2,728,306 under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on reducing plasma cholesterol and atherosclerosis using microRNA-30C analog C2. The research initiative, which commenced on September 24, 2025, and extends through August 31, 2027, focuses on developing and validating a novel synthetic...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Connecticut Health Center a $227,878 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) effective June 20, 2025, with completion targeted for January 31, 2028. This research initiative investigates the role of TRPM7 (Transient Receptor Potential Protein, Melastatin Family Member 7) in macrophage-mediated atherosclerosis development. The project will generate...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Connecticut Health Center a $611,014 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) effective September 1, 2025, through July 31, 2027. This award supports the development of adeno-associated virus (AAV) therapies targeting TNNT2-associated cardiac disorders, including hypertrophic cardiomyopathy and dilated cardiomyopathy. The project addresses a...
- Federal Grant Award Summary Emory University received a $162,080 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective March 13, 2026, with a completion date of September 11, 2027. This research project, titled "Defining the Function of C/EBP-Beta and Its Downstream Target PSMB9 in Atherosclerosis," will investigate the molecular mechanisms underlying atherosclerosis development,...
- Federal Grant Award Summary The University of Arizona received a $1.47M Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 1, 2025, with a completion date of May 31, 2029. The award funds basic research investigating the role of hepatocyte transmembrane protein 141 (TMEM141) in lipoprotein metabolism and atherosclerosis. The research team will utilize genetically modified mouse models and...